Can famotidine and omeprazole be combined on a once-daily basis?

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 6, 2007, Pages 689-694

  Fändriks, Lars ^a   Lönroth, Hans ^a   Pettersson, Anders ^b   Vakil, Nimish ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Orexo AB   (Sweden)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antisecretory agents; Gastric; Hydrogen ions; pH; Secretion; Stomach

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; MONOTHERAPY; NORMAL HUMAN; PATIENT COMPLIANCE; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FAMOTIDINE; HUMANS; OMEPRAZOLE;

EID: 34248530307     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601026665     Document Type: Article

References (21)

1. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001;15:355-70.
2. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307.
3. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastr Hepatol 2001;13(Suppl 1):S35-41.
4. Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004;30(126):7800-11.
5. Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, et al. Effect of low-dose rapeprazole and omeprazole on gastric acidity: results of a double-blind, randomized, plazebo-controlled, three-way crossover study in healthy subjects. Aliment Pharm Ther 2004;20:899-907.
6. Arnestad JS, Kleveland PM, Waldum HL. In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther 1997;11: 355-8.
7. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990;35:976-83.
8. Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98: S40-8.
9. Hoogwerf WA, Pasricha PJ. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal disease. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. ch 37, pp 1005-20.
10. Katz PO, Tutuian R. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 2001;15:371-84.
11. Vakil N, Guda N, Partington S. The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. Aliment Pharmacol Ther 2006;1(23): 649-53.
12. Hamlet A, Stage L, Lonroth H, Cahlin C, Nystrom C, Pettersson A. A novel tablet-based 13C urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy. Scand J Gastroenterol 1999;34: 367-74.
13. Talley NJ, Lauritsen K, Tunturi-Hihnala H, Lind T, Moum B, Bang C, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
14. Komazawa Y, Adachi K, Mihara T, Ono M, Kawamura A, Fujishiro H, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:678-82.
15. Furuta T, Shirai N, Sugimoto M, et al. Effect of concomitant dosing of famotidine with lanzoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharm Ther 2005;22:67-74.
16. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14(10):1267-72.
17. Vakil N. New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;19:1041-9.
18. Metz DC, Vakil N, Keeffe EB, Lichtenstein GR. Advances in gastrointestinal pharmacotherapy. Clin Gastroenterol Hepatol 2005;3:1167-79.
19. Dent J, Kahrilas P, Hatlebakk J, Vakil N, Denison H, Franzen S, et al. A randomized, comparative efficacy study of three doses of AZD0865 and esomeprazole in patients with non-erosive reflux disease. Gastroenterology 2006;130 Suppl 2:176:S1204 [abstract].
20. Mann SG, Cottrell J, Murakami A, Stauffer L, Rao AN. Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. Aliment Pharmacol Ther 1997;11:121-7.
21. Goddard A, Jessa M, Barrett D, Shaw P, Idstrom J, Cederberg C, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-67.